Meet our team!
Investigator - Dr. Jean-Claude Tardif
Jean-Claude Tardif is Director of the Montreal Heart Institute Research Center and Professor of Medicine at the University of Montreal. He received his doctorate in medicine in 1987 from the University of Montreal and pursued further training in cardiology and research in Montreal and Boston until 1994. Dr. Tardif holds the Canada Research Chair in Personalized Medicine and the Endowed Research Chair in Atherosclerosis at the University of Montreal. He is the Scientific Director of the Montreal Health Innovation Coordination Center (MHICC).
His research focuses on genomic and molecular aspects of atherosclerosis and related diseases. It also focuses on animal models and relies on mechanistic and observational clinical studies as well as early clinical trials and large international randomized clinical trials. Dr. Tardif is, or has been, the principal investigator or director for several large international clinical trials in atherosclerosis and other cardiovascular diseases. He and his team created the Beaulieu-Saucier Pharmacogenomics Center at the University of Montreal's Montreal Heart Institute and the Center of Excellence in Personalized Medicine (CEPMed), which was funded by the Canadian Network of Centers of Excellence and various pharmaceutical and biotechnology companies.
Over the course of his career, Dr. Tardif has authored more than 750 scientific papers and has won numerous awards, including the Canadian Cardiovascular Society Research Excellence Award, the Canadian Institutes of Health Research Distinguished Lecturer Award, the BIOQuebec Genesis Award (for outstanding contribution to life sciences), and the Armand-Frappier Award from the Government of Quebec, the highest scientific honor. He was also named scientific personality of the year by the daily La Presse. As a result of his achievements, he was named a Fellow of the Canadian Academy of Health Sciences (FCAHS) and was recently sworn into the Order of Canada, the country's highest honor.
COLCOT-T2D Project Steering Committee
The steering committee, under the leadership of Dr. Jean-Claude Tardif, is composed of local and international members who are experts in their field and bring their expertise to the design and implementation of this project. The committee includes 4 cardiologists, 2 endocrinologists, 2 general practitioners, 1 neurologist, 1 neuropsychologist, 2 members of Diabetes Quebec and 1 patient partner.
The clinical research team is proud and very motivated to be part of the COLCOT-T2D research project which will allow us to better understand, analyze and treat type 2 diabetes and cardiovascular disease.
Our team consists of nurses with extensive expertise in cardiology and regulatory and administrative support.
Our vast experience in cardiology, dyslipidemia and diabetes allows us to offer you quality support and guidance.
Our role is to accompany you every step of the way as you participate in this research project. Your participation is of great importance for this project and we would like to thank you. Our team is dynamic and passionate and you can count on our values of professionalism, dedication, ethics, teamwork and respect for the population involved in the research project.
Precision Medicine Sub-Study Research Team
The team in charge of recruiting patients for the two COLCOT-T2D precision medicine sub-studies (pharmacogenomic study and proteomic study) is composed of research nurses, recruiting officers and biosample managers. We have over 15 years of experience in clinical research and have developed valuable experience in conducting remote clinical research projects over the past few years. We will accompany you throughout this study.
"Through your participation in the COLCOT T2D sub-studies, you are supporting one of the flagship research projects of the Montreal Heart Institute, whose goal is to investigate the genetic bases and other underlying risk factors for cardiovascular disease and related pathologies.
As this bold project demonstrates, your support is invaluable as it allows the Montreal Heart Institute to remain at the forefront of emerging treatments for, among other things, cardiovascular diseases and their relationship with genes, for the greater benefit of patients and the entire community.
On behalf of the Montreal Heart Institute Research Center, we would like to thank you for your generous participation in supporting this new initiative. The work we do every day would not be possible without your participation.
Thank you for your valuable support, you are certainly contributing to the advancement of cardiovascular medicine."